Furthermore, TTLL4 inhibition markedly enhanced tumor cell apoptosis induced by proapoptotic agents, suggesting that targeting TTLL4 may potentiate the efficacy of existing HCC therapies, such as transarterial chemoembolization (TACE) and lenvatinib,32 thus suggesting the potential for the development of novel combination treatment strategies. The gene discussed is TTLL4; the disease is neoplasm.